Key Highlights

  • 239 thousand USD is the approximate Revenue Insight Molecular Diagnostics (NASDAQ:IMDX) reported for the second quarter of 2026, down from USD 518 thousand a year earlier, with most of it generated by laboratory services.
  • 11.3 million USD was the GAAP net loss, or USD 0.31 per share, in the second quarter, while the non-GAAP net loss was USD 8.3 million, or USD 0.23 per share, according to the company release.
  • 18.7 million USD in cash, equivalents and restricted cash was held on June 30, 2026, against USD 9.3 million of operating cash used in the second quarter and USD 16.9 million over the first six months.
  • 5:00 p.m. ET on November 16, 2026 is when the live webinar for Insight Molecular Diagnostics (NASDAQ:IMDX) begins, following results scheduled for release after the market closes for the quarter ended September 30, 2026.

What Investors Expect From Insight Molecular Diagnostics (NASDAQ:IMDX) on November 16, 2026

The company is scheduled to release third quarter 2026 results after the market closes on Monday, November 16, 2026, followed by a live webinar with questions at 2:00 p.m. PT, or 5:00 p.m. ET. Insight Molecular Diagnostics is a transplant diagnostics company whose GraftAssureDx kit was submitted for FDA review in late March 2026. Second quarter revenue of USD 239 thousand compared with USD 518 thousand in the prior-year quarter, a calculated decline of about 54%, and Gross Profit was USD 157 thousand, a Margin of 65.7%.

The Rationale: Last Reported Quarter and Management Outlook for Insight Molecular Diagnostics (NASDAQ:IMDX)

Second quarter operating expenses were USD 11.6 million, including a non-cash contingent consideration charge of USD 2.3 million. The GAAP net loss was USD 11.3 million, or USD 0.31 per share, and the six-month net loss reached USD 15.6 million, or USD 0.44 per share. Adjusted EBITDA showed a loss of USD 7.8 million. In late July 2026 the FDA completed the current phase of its substantive review on time and requested additional information, which the company described as typical in a regulatory authorization process. The company has not issued numeric revenue or cash burn guidance, but it expects outgoing free Cash Flow to narrow in the second half of 2026 and Research and Development expense to stabilize near recent levels.

Valuation, Liquidity and Risks for Insight Molecular Diagnostics (NASDAQ:IMDX)

At June 30, 2026, cash, equivalents and restricted cash totaled USD 18.7 million, including USD 17.8 million of Balance Sheet cash and equivalents. Total Assets were USD 29.4 million against total liabilities of USD 50.7 million, leaving a shareholders' Deficit of USD 21.3 million, largely because noncurrent contingent consideration stood at USD 39.5 million. Shares outstanding were 32.6 million, with a pro forma fully diluted count of 36.9 million including pre-funded warrants. Operating cash use of USD 9.3 million in the quarter implies a calculated coverage of roughly two quarters at that pace, which makes financing and regulatory timing the central risks.

Where Things Stand

Insight Molecular Diagnostics (NASDAQ:IMDX) approaches its November 16, 2026 report with second quarter revenue of USD 239 thousand, a GAAP net loss of USD 11.3 million and cash of USD 18.7 million. The GraftAssureDx submission, filed in late March 2026, remains under FDA review after an on-time information request in late July. Management has not provided numeric guidance but has said outgoing free cash flow should narrow in the second half. The coming results will show whether spending is easing against gross profit of USD 157 thousand and how the company intends to fund operations until authorization is received.